A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients: a retrospective cohort study

Table 7 Site of recurrence and the cause of death in premenopausal breast cancer patients treated with tamoxifen or toremifene

	Tamoxifen (n = 240)	Toremifene (n = 212)
Recurrences	23(9.6%)	6(2.8%) 2
Logoregional	14
Distant	15	4
Lymph nodes or other soft tissues	3	2
Bone	8	2
Liver	4	1
Contralateral breast cancer	1	0
Brain	2	0
Lung	4	0
Deaths	5(2.1%)	0(0%)
Breast cancer	4	0
Other reasons	1	0

In the tamoxifen group, there were 12 patients with multiple site of recurrence, of which 7 had more than one site where distant metastases were detected, 5 had concurrent locoregional and one or more sites of distant recurrence. In the toremifene group, there was 1 patient who had concomitant bone and liver metastases.

ISSN: 1471-2407